P R Walker

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
    P R Walker
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Immunol 158:4521-4. 1997
  2. ncbi The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells
    P R Walker
    Laboratory of Tumor Immunology, Division of Oncology, and Department of Neurosurgery, University Hospital Geneva, Geneva, Switzerland
    J Immunol 165:3128-35. 2000
  3. ncbi Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
    P Saas
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Clin Invest 99:1173-8. 1997
  4. ncbi Tumor expression of Fas ligand (CD95L) and the consequences
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 Rue Micheli du Crest, CH 1211, Geneva 14, Switzerland
    Curr Opin Immunol 10:564-72. 1998
  5. ncbi Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, CH 1211 Geneva 14, Switzerland
    Cell Immunol 206:51-8. 2000

Collaborators

  • P Saas
  • E G Van Meir
  • P Y Dietrich
  • N de Tribolet
  • A L Quiquerez
  • V Schnuriger
  • G Perrin
  • M Hahne
  • J Tschopp
  • L French

Detail Information

Publications5

  1. ncbi Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back
    P R Walker
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Immunol 158:4521-4. 1997
    ..The potential interactions between tumor cells and the host immune response are thus more complex than previously thought; their elucidation will benefit the rational design of cancer immunotherapy strategies...
  2. ncbi The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells
    P R Walker
    Laboratory of Tumor Immunology, Division of Oncology, and Department of Neurosurgery, University Hospital Geneva, Geneva, Switzerland
    J Immunol 165:3128-35. 2000
    ..This observation correlated with potent ex vivo cytotoxicity of brain-infiltrating CTLs, specific for the immunodominant epitope CW3170-179 expressed on P815-CW3 tumor cells...
  3. ncbi Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
    P Saas
    Division of Oncology, University Hospital, Geneva, Switzerland
    J Clin Invest 99:1173-8. 1997
    ..Overall, our findings suggest that FasL-induced apoptosis by astrocytoma cells may play a significant role in both immunosuppression and the regulation of tumor growth within the central nervous system...
  4. ncbi Tumor expression of Fas ligand (CD95L) and the consequences
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 Rue Micheli du Crest, CH 1211, Geneva 14, Switzerland
    Curr Opin Immunol 10:564-72. 1998
    ..The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment...
  5. ncbi Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation
    P R Walker
    Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, CH 1211 Geneva 14, Switzerland
    Cell Immunol 206:51-8. 2000
    ..Understanding how Fas may be differentially regulated in vivo and in vitro is an important issue for the optimal manipulation of T cells for adoptive immunotherapy protocols...